Risvutatug rezetecan

Antibody–drug conjugate

Also known as GSK5764227, HS-20093

Filedunder review

Evidence outlook · regulatory review

Small Cell Lung Cancer: application under NMPA review

China's NMPA accepts the BLA for HS-20093 (risvutatug rezetecan) in small cell lung cancer (2026-09-02). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Also in development:Non-Small Cell Lung Cancer · Phase 3Esophageal Squamous Cell Carcinoma · Phase 3

Featured evidence outside this drug's tracked markets:ARTEMIS-011 (NCT06935409) · Osteosarcoma · Phase 3 · completed · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Esophageal Squamous Cell Carcinoma
NCT07621601 · Hansoh BioMedical R&D Company
2026-07-31 – 2032-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
NCT07099898 · GlaxoSmithKline
2025-08-11 – 2029-09-28 · Neoplasms, Lung
What this study did
NCT06526624 · Hansoh BioMedical R&D Company
2024-09-30 – 2029-01-31 · Limited-stage Small-cell Lung Cancer
What this study did
Other / comorbidity
NCT07802704 · GlaxoSmithKline
2026-09-01 – 2029-12-05 · Neoplasms, Prostate
What this study did
NCT06935409 · Hansoh BioMedical R&D Company
2025-04-25 – 2026-09-07 · Osteosarcoma
What this study did
Phase 2 (8)
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
NCT06052423 · Hansoh BioMedical R&D Company
2024-11-30 – 2027-06-30 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
Other / comorbidity
NCT07408063 · University Health Network, Toronto
2026-04-27 – 2031-03-01 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT07230106 · Jiangsu HengRui Medicine Co., Ltd.
2025-12-08 – 2029-12 · Prostate Cancer
What this study did
NCT05830123 · Hansoh BioMedical R&D Company
2023-06-08 – 2027-12-31 · Osteosarcoma, Sarcoma
What this study did
NCT06007729 · Hansoh BioMedical R&D Company
2023-12-18 – 2027-12-12 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06112704 · Hansoh BioMedical R&D Company
2024-02-06 – 2026-12-31 · Advanced Solid Tumor
What this study did
NCT06001255 · Hansoh BioMedical R&D Company
2024-01-18 – 2025-12-31 · Metastasis Castration Resistant Prostate Cancer(mCRPC)
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT07736612 · Zhejiang University
2026-08-15 – 2029-12-30 · Pancreatic Cancer, RAS Mutations or Amplifications
What this study did
NCT07602855 · GlaxoSmithKline
2026-09-09 – 2029-12-24 · Neoplasms, Lung
What this study did
NCT07602777 · GlaxoSmithKline
2026-06-22 – 2029-11-23 · Sarcoma
What this study did
Phase 1 (16)
Non-Small Cell Lung Cancer
NCT07899086 · Hansoh BioMedical R&D Company
2026-11-10 – 2030-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT06963502 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-05-30 – 2030-04-30 · Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
What this study did
NCT06621563 · Hansoh BioMedical R&D Company
2024-12-14 – 2026-12-01 · Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
What this study did
Small Cell Lung Cancer
NCT07892625 · Hansoh BioMedical R&D Company
2026-11-15 – 2029-09-15 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT07063407 · Shanghai Hansoh Biomedical Co., Ltd
2025-07-31 – 2027-05-31 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
Other / comorbidity
NCT07277270 · GlaxoSmithKline
2025-12-03 – 2030-05-01 · Neoplasms
What this study did
NCT06699576 · Hansoh BioMedical R&D Company
2024-12-20 – 2028-12-30 · Osteosarcoma, Soft Tissue Sarcoma (STS)
What this study did
NCT07115446 · Hansoh BioMedical R&D Company
2025-08-19 – 2028-12 · Advanced Prostate Cancer
What this study did
NCT06332170 · Hansoh BioMedical R&D Company
2024-04-26 – 2028-05-30 · Advanced Solid Tumor
What this study did
NCT07462923 · Hansoh BioMedical R&D Company
2026-01-29 – 2028-03-31 · Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05277051 · GlaxoSmithKline
2022-03-22 – 2027-08-31 · Neoplasms
What this study did
NCT06825624 · Hansoh BioMedical R&D Company
2024-10-03 – 2026-12-31 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT06769425 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-05-07 – 2026-08-31 · Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC, Advanced Prostate Cancer, Advanced Gastric Cancer
What this study did
NCT07186452 · Hansoh BioMedical R&D Company
2025-09-23 – 2026-08-31 · Advanced Solid Tumors
What this study did
NCT05276609 · Shanghai Hansoh Biomedical Co., Ltd
2021-11-28 – 2023-12-31 · Advanced Solid Tumor
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Esophageal Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Risvutatug Rezetecan: this drugPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03189719: Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590).
NCT02564263: Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181).
TislelizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Risvutatug rezetecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Osteosarcoma, Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2026-12-30 · NCT06699576 · CT.gov ↗
What to watch
Phase 1Advanced Gastric and Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT07462923 · CT.gov ↗
What to watch
2027 (6)
July 2027 (1)
Phase 1Glioblastoma (GBM), Brain MetastasasesRecruiting
Est. primary completion 2027-07 · NCT07268053 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1/2SarcomaRecruiting
Est. primary completion 2027-11-05 · NCT07602777 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-05 · NCT07099898 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT06526624 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Advanced Prostate CancerRecruiting
Est. primary completion 2027-12 · NCT07115446 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07899086 · CT.gov ↗
What to watch
2028 (7)
February 2028 (1)
Phase 1NeoplasmsRecruiting
Est. primary completion 2028-02-14 · NCT07277270 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-30 · NCT07824882 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Pancreatic Cancer, RAS Mutations or AmplificationsNot yet recruiting
Est. primary completion 2028-08-30 · NCT07736612 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-09-15 · NCT07892625 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Prostate CancerRecruiting
Est. primary completion 2028-12 · NCT07230106 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06963502 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07464327 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 1/2Gastrointestinal NeoplasmsRecruiting
Est. primary completion 2029-01-09 · NCT06885034 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Neoplasms, LungRecruiting
Est. primary completion 2029-06-22 · NCT07602855 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Neoplasms, ProstateRecruiting
Est. primary completion 2029-12-05 · NCT07802704 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07408063 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT07621601 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 September 2026Filing acceptedChina's NMPA accepts the BLA for HS-20093 (risvutatug rezetecan) in small cell lung cancer
CN, NMPA · Hansoh Pharmaceutical Group · Source ↗
10 July 2026Topline resultARTEMIS-008 Phase 3: overall survival primary endpoint met in relapsed small cell lung cancer
Hansoh Pharmaceutical Group · Source ↗